RECRUITING

Imaging Retinal Vasculature in Infant Eyes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

Official Title

Elucidating Perifoveal Vasculature Development in Infants

Quick Facts

Study Start:2024-10-03
Study Completion:2027-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05558059

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 2 Months
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
  2. * Parent/Legal Guardian is able and willing to consent to study participation for the infant
  3. * Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit
  1. * Participant or Parent/Legal Guardian unwilling or unable to provide consent
  2. * Infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
  3. * Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)

Contacts and Locations

Study Contact

Xi Chen, MD
CONTACT
(919) 684-8434
xi2.chen@duke.edu
Michelle N McCall
CONTACT
(919) 684-0544
michelle.mccall@duke.edu

Principal Investigator

Xi Chen, MD
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University
Durham, North Carolina, 27710
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Duke University

  • Xi Chen, MD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-03
Study Completion Date2027-08-31

Study Record Updates

Study Start Date2024-10-03
Study Completion Date2027-08-31

Terms related to this study

Keywords Provided by Researchers

  • Retinopathy of Prematurity
  • Optical Coherence Tomography
  • Perifoveal vasculature
  • Vascular development
  • Macular edema
  • ROP
  • OCT
  • Prematurity
  • Optical Coherence Tomography Angiography
  • OCTA

Additional Relevant MeSH Terms

  • Retinopathy of Prematurity